Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Prime Medicine (PRME) Return on Sales (2024 - 2025)

Prime Medicine (PRME) has disclosed Return on Sales for 2 consecutive years, with 56.71% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales fell 3735.0% year-over-year to 56.71%, compared with a TTM value of 44.22% through Dec 2025, up 2144.0%, and an annual FY2025 reading of 44.08%, up 2158.0% over the prior year.
  • Return on Sales was 56.71% for Q4 2025 at Prime Medicine, down from 43.13% in the prior quarter.
  • Across five years, Return on Sales topped out at 19.37% in Q4 2024 and bottomed at 367.92% in Q2 2024.